Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4220MR)

This product GTTS-WQ4220MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000133.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4220MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9875MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ11847MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ12735MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ9699MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ3070MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ12997MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ5355MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ5288MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD124
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW